Back to News
Market Impact: 0.15
NImmune Biopharma Presented New Data at ACG 2026 Supporting the Efficacy and Safety of Innovative LANCL2 Medicines Targeting a Novel Mechanism in Hard-to-Treat IBD
Source: Business Wire
Healthcare & BiotechArtificial Intelligence
NImmune reported ACG 2026 data it says support omilancor and NIM-1324 for hard-to-treat inflammatory bowel disease (IBD). The announcement highlights LANCL2 and the company's TITAN-X AI platform, but the article provides no efficacy figures or further study details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- Applied Materials’ $5 billion AI lab aims to cut chip development time in half—and restore Silicon Valley’s edge
- China's exports likely grew by double-digits in September
- Meta’s Muse models reach the AI frontier—and kill any hopes to ‘pace’ it
- Singapore third-quarter GDP growth softens from four-year high but beats estimates
- FBI arrests OpenAI employee accused of planting secret recording device in conference room
- We're upgrading our Goldman Sachs rating after a strong quarter bodes well for the future
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Write an Investment Memo with AI: A Decision-Record Template
- Best AI to Write Earnings Notes for Sell-Side Analysts